Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityConvertible DebtCurrent AssetsGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityNon-Current AssetsNon-Current DebtNon-Current Deferred Tax LiabilityOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetReceivables - OtherRetained EarningsShareholder's EquityShort term DebtShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current Liabilities
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Coherus Oncology (CHRS) Retained Earnings (2016 - 2025)

Historic Retained Earnings for Coherus Oncology (CHRS) over the last 13 years, with Q3 2025 value amounting to -$1.3 billion.

  • Coherus Oncology's Retained Earnings rose 1032.94% to -$1.3 billion in Q3 2025 from the same period last year, while for Sep 2025 it was -$1.3 billion, marking a year-over-year increase of 1032.94%. This contributed to the annual value of -$1.6 billion for FY2024, which is 180.48% up from last year.
  • Per Coherus Oncology's latest filing, its Retained Earnings stood at -$1.3 billion for Q3 2025, which was up 1032.94% from -$1.3 billion recorded in Q2 2025.
  • In the past 5 years, Coherus Oncology's Retained Earnings ranged from a high of -$935.7 million in Q1 2021 and a low of -$1.6 billion during Q1 2025
  • For the 5-year period, Coherus Oncology's Retained Earnings averaged around -$1.3 billion, with its median value being -$1.3 billion (2025).
  • As far as peak fluctuations go, Coherus Oncology's Retained Earnings crashed by 3763.99% in 2021, and later soared by 1206.75% in 2025.
  • Over the past 5 years, Coherus Oncology's Retained Earnings (Quarter) stood at -$1.0 billion in 2021, then dropped by 27.79% to -$1.3 billion in 2022, then decreased by 17.73% to -$1.6 billion in 2023, then increased by 1.8% to -$1.6 billion in 2024, then rose by 13.26% to -$1.3 billion in 2025.
  • Its last three reported values are -$1.3 billion in Q3 2025, -$1.3 billion for Q2 2025, and -$1.6 billion during Q1 2025.